In vivo mapping of brainstem nuclei functional connectivity disruption in Alzheimer's disease by Serra, Laura et al.
lable at ScienceDirect
Neurobiology of Aging 72 (2018) 72e82Contents lists avaiNeurobiology of Aging
journal homepage: www.elsevier .com/locate/neuagingIn vivo mapping of brainstem nuclei functional connectivity
disruption in Alzheimer’s disease
Laura Serra a,1, Marcello D’Amelio b,c,1, Carlotta Di Domenico a, Ottavia Dipasquale d,
Camillo Marra e, Nicola Biagio Mercuri f,g, Carlo Caltagirone g,h, Mara Cercignani a, i,
Marco Bozzali a, i,*
aNeuroimaging Laboratory, IRCCS Santa Lucia Foundation, Rome, Italy
b Laboratory Molecular Neurosciences, IRCCS Santa Lucia Foundation, Rome, Italy
cUnit of Molecular Neurosciences, Department of Medicine, University Campus-Biomedico, Rome, Italy
dDepartment of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom
e Institute of Neurology, Catholic University, Rome, Italy
f Laboratory of Experimental Neurology, IRCCS Santa Lucia Foundation, Rome, Italy
gDepartment of Systems Medicine, University of Rome ‘Tor Vergata’, Rome, Italy
hDepartment of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, Italy
iDepartment of Neuroscience, Brighton & Sussex Medical School, University of Sussex, Brighton, East Sussex, United Kingdoma r t i c l e i n f o
Article history:
Received 19 December 2017
Received in revised form 7 August 2018
Accepted 14 August 2018
Available online 23 August 2018
Keywords:
Alzheimer’s disease
VTA
LC
Brain disconnection
Neuropsychiatric symptoms* Corresponding author at: Department of Neuros
Medical School, University of Sussex, Brighton, East S
873509; fax: þ44 (0) 1273 876721.
E-mail address: m.bozzali@bsms.ac.uk (M. Bozzali)
1 These authors contributed equally to the article.
0197-4580/ 2018 The Author(s). Published by Elsevie
https://doi.org/10.1016/j.neurobiolaging.2018.08.012a b s t r a c t
We assessed here functional connectivity changes in the locus coeruleus (LC) and ventral tegmental area
(VTA) of patients with Alzheimer’s disease (AD). We recruited 169 patients with either AD or amnestic
mild cognitive impairment due to AD and 37 elderly controls who underwent cognitive and neuro-
psychiatric assessments and resting-state functional magnetic resonance imaging at 3T. Connectivity was
assessed between LC and VTA and the rest of the brain. In amnestic mild cognitive impairment patients,
VTA disconnection was predominant with parietal regions, while in AD patients, it involved the posterior
nodes of the default-mode network. We also looked at the association between neuropsychiatric
symptoms (assessed by the neuropsychiatric inventory) and VTA connectivity. Symptoms such as
agitation, irritability, and disinhibition were associated with VTA connectivity with the parahippocampal
gyrus and cerebellar vermis, while sleep and eating disorders were associated with VTA connectivity to
the striatum and the insular cortex. This suggests a contribution of VTA degeneration to AD patho-
physiology and to the occurrence of neuropsychiatric symptoms. We did not ﬁnd evidence of LC
disconnection, but this could be explained by the size of this nucleus, which makes it difﬁcult to isolate.
These results are consistent with animal ﬁndings and have potential implications for AD prognosis and
therapies.
 2018 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alzheimer’s disease (AD) is clinically characterized by neuro-
psychiatric symptoms in addition to a progressive cognitive decline
(Alves et al., 2017). The relevance of neuropsychiatric symptoms has
become increasingly evident as demonstrated by their early
occurrence in cognitively intact individuals who subsequently
develop dementia (Masters et al., 2015). The cholinergic hypothesiscience, Brighton and Sussex
ussex, UK. Tel.: 44 (0) 1273
.
r Inc. This is an open access article(Bartus et al., 1982) of AD has been extensively investigated,
showing that cholinergic dysfunctions in the basal forebrain ac-
count formemory deﬁcits in typical AD (Theoﬁlas et al., 2015). It has
been proposed that AD symptoms may also result from structural
and functional abnormalities of the dopaminergic (Theoﬁlas et al.,
2015) and noradrenergic (Borodovitsyna et al., 2017) systems. The
noradrenergic (Borodovitsyna et al., 2017) or dopaminergic stimu-
lation (Theoﬁlas et al., 2015) leads to a signiﬁcant improvement of
cognitive functions, while their simultaneous stimulation reduces
both beta amyloid (Ab) load and tau pathology (Theoﬁlas et al.,
2015). Among the dopaminergic-rich nuclei, the ventral
tegmental area (VTA) is known to be part of the reward system
(Krebs et al., 2011; Nobili et al., 2017), and dopaminergic VTAunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tions, ranging from memory and motivational processes (Krebs
et al., 2011; Nobili et al., 2017) to sleep-wake behaviors (Eban-
Rothschild et al., 2016). Consistently, dopaminergic dysfunctions
have been implicated in the occurrence of various neuropsychiatric
symptoms, including mood disorders (Ashok et al., 2017; Schaeffer
& Berg, 2017), apathy (Chong and Husain, 2016), sleep (Kim et al.,
2017), and eating disorders (Kessler et al., 2016). Most noradren-
ergic neurons originate from the locus coeruleus (LC), whose pro-
jections reach the entire cerebral cortex, the thalamic nuclei, and
the hippocampus (Robertson et al., 2013). LC undergoes signiﬁcant
functional and structural modiﬁcations in AD (Theoﬁlas et al., 2015)
as conﬁrmed by postmortem observations (Francis et al., 1985;
Storga et al., 1996) and supported by neurophysiological studies
(Benussi et al., 2017; Gonsalvez et al., 2017). In postmortem studies,
LC has been shown containing hyperphosphorylated tau, the major
component of neuroﬁbrillary tangles (NFT), not only in AD patients
but also in nondemented individuals decades before the typical age
of clinical onset of AD (Braak and Del Tredici, 2011a; Braak and Del
Tredici, 2011b; Pamphlett and Kum Jew, 2015). According to this
model, hyperphosphorylated tau that forms early on in life in LC
neurons would spread via cell-to cell transfer to other neurons to
produce NFT (Braak and Del Tredici, 2011a). Damage to the LC with
consequent decrease in noradrenaline would also promote the
formation of Ab plaques (Heneka et al., 2006; Pamphlett and Kum
Jew, 2015).
Taken together, these data suggest that a loss of monoaminergic
neuronsmight contribute to AD pathophysiology andmight explain
some of its clinical manifestation, particularly the neuropsychiatric
symptoms (Köhler et al., 2016).
A recent study (Nobili et al., 2017), performed in a transgenic
mouse model of AD, showed that the progressive degeneration of
dopaminergic neurons fromVTA results in lower dopamine outﬂow
in the hippocampus and nucleus accumbens, which correlates with
deﬁcits in memory and reward processing. Importantly, this
dopaminergic loss precedes Ab plaque deposition, thus represent-
ing one of the earliest pathological changes in AD. More recently,
evidence of VTA degeneration in association with memory deﬁcits
has been provided in patients with AD and mild cognitive impair-
ment (De Marco and Venneri., 2018). Interestingly, a recent resting-
state functional magnetic resonance imaging (fMRI) study
demonstrated in healthy individuals that VTA and the substantia
nigra pars compacta are functionally connected to the default mode
network (DMN) (Bär et al., 2016), which is known being selectively
disrupted in AD since early clinical stages (Gili et al., 2011).
Neuropsychiatric symptoms are also part of the clinical picture of
AD since the early disease stages (Serra et al., 2010), and dopami-
nergic dysfunction is likely to play a pathophysiological relevant
role for their manifestation.
We hypothesize that, if a loss of dopaminergic neurons occurs in
patients with AD from an early stage, possibly preclinical, and a
similar pattern of degeneration occurs to noradrenergic neurons
originating from the LC, this neuronal loss should result in lower
functional connectivity (FC) between the VTA and/or the LC and the
rest of the brain. In addition, these changes likely account for the
occurrence and severity of cognitive and behavioral symptoms.
While we are unable to address directly the ﬁrst 2 hypotheses,
we focused on the remaining 2. To interrogate these hypotheses, we
recruited a large sample of patients with either AD or amnestic mild
cognitive impairment (a-MCI) due to AD, and we used resting-state
fMRI as a surrogate measure of neuronal degeneration. fMRI as-
sesses the connectivity between brain areas by measuring the
correlation between spontaneous ﬂuctuations in neuronal activity
occurring at remote locations (Biswal et al., 1995; Fox et al., 2005). A
loss of neurons within a speciﬁc nucleus, such as LC or VTA, isexpected to result in altered connectivity with its projection areas.
It was previously shown that resting-state fMRI may be used to
measure the connectivity of small subcortical structures such as the
brainstem nuclei (Bianciardi et al., 2018), comparable in size to VTA
and LC.
2. Methods
2.1. Participants
A cohort of 169 participants, 84 of them with a diagnosis of
probable AD (McKhann et al., 2011) or Alzheimer’s clinical syn-
drome (Jack et al., 2018), 48 with a diagnosis of a-MCI (Albert et al.,
2011), and 37 healthy elderly subjects (HS) were enrolled for this
study. The diagnosis of probable AD was done according to the
clinical criteria of the National Institute of Neurological and
Communicative Disorders and Stroke-Alzheimer’s Disease and
Related Disorders Association (McKhann et al., 2011) and ﬁt with
the criteria for Alzheimer’s clinical syndrome reported more
recently by Jack et al. (2018). The diagnosis of a-MCI was performed
according to current available criteria (Albert et al., 2011). Patients
with a-MCI could be either single (n ¼ 24) or multiple (n ¼ 24)
domains and had not to respond to the diagnostic criteria for major
cognitive disorder (American Psychiatric Association (APA), 2013),
showing a clinical dementia rating (Hughes et al., 1982) score not
exceeding 0.5. Cognitive proﬁle characterized by episodic memory
impairment at onset, episodic memory deﬁcit documented at
formal testing, andmedial temporal lobe atrophy (see Section 2.3.1)
conﬁrmed that all individuals had a proﬁle supporting Alzheimer’s
clinical syndrome at different stages.
Cognitively normal subjects showing the presence of signiﬁcant
medial temporal lobe atrophy were excluded. All recruited subjects
with a Hachinski score (Hachinski et al., 1975) higher than 4 were
excluded. Major systemic, psychiatric, and other neurological ill-
nesses (with a special attention to Parkinson disease and parkin-
sonism) were also carefully investigated and excluded in all
participants. Finally, subjects had to be right-handed, as assessed by
the Edinburgh Handedness Inventory (Büsch et al., 2010). The main
demographic and clinical characteristics of the participants are
summarized in Table 1, together with data about their medication.
This study was approved by the Ethical Committee of Santa
Lucia Foundation, and written informed consent was obtained from
all participants before study initiation. All procedures performed in
this study were in accordance with the 1964 Helsinki declaration
and its later amendments or comparable ethical standards.
2.2. Neuropsychological and behavioral assessment
All participants underwent an extensive neuropsychological
battery covering all cognitive domains, which included (1) verbal
episodic long-term memory: 15-Word List (immediate, 15-minute
delayed recall and recognition) (Carlesimo et al., 1996); Short
Story Test (immediate and 20-minute delayed recall) (Carlesimo
et al., 2002); (2) visuospatial long-term memory: Complex Rey’s
Figure (immediate and 20-minute delayed recall) (Carlesimo et al.,
2002); (3) short-term and working memory: Digit span (forward
and backward) and the Corsi Block-Tapping task (forward and
backward) (Monaco et al., 2013); (4) executive functions: Phono-
logical Word Fluency (Carlesimo et al., 1996) and Modiﬁed Card
Sorting Test (Nocentini et al., 2002); (5) language: naming objects
subtest of the BADA (‘‘Batteria per l’Analisi dei Deﬁcit Afasici,’’
Italian for ‘‘Battery for the analysis of aphasic deﬁcits’’) (Miceli et al.,
1991); (6) Reasoning: Raven’s Coloured Progressive Matrices
(Carlesimo et al., 1996); (7) constructional praxis: copy of simple
drawings with and without landmarks (Carlesimo et al., 1996) and
Table 1
Principal demographic and clinical characteristics of the participants
Mean (SD) AD a-MCI HS Statistics p-value
N ¼ 84 N ¼ 48 N ¼ 37
Age [y] 73.1 (6.2) 71.8 (7.4) 70.7 (5.3) F2.166 ¼ 1.99 0.139
Gender (M/F) 34/50 24/24 16/21 Chi12 < 1.13 <0.78
Education [y] 9.3 (4.3)c 9.9 (4.6)b 12.6 (3.5) F2.166 ¼ 8.01 0.001
MMSE score 20.4 (4.0)c,a 26.1 (1.6)b 28.3 (1.9) F2.166 ¼ 105.05 0.000
MTA score 2.8 (0.8)c,a 2.2 (0.9)b 0.7 (0.6) F2.166 ¼ 88.41 0.000
Medication: N (%)
Benzodiazepines 7/84 (8%) 6/48 (12.5%) - Chi12 ¼ 0.6 0.43
Antidepressants 21/84 (25%) 14/48 (29.1%) - Chi12 ¼ 0.2 0.63
Neuroleptics 6/84 (7%) - - - -
AChEIs 35/84 (41.6%) - - - -
Key: a-MCI, amnestic mild cognitive impairment; AChEIs, Acetylcholinesterase inhibitors; AD, Alzheimer’s disease; HS, healthy subjects; MMSE, Mini-Mental State Exami-
nation; MTA, medial temporal atrophy scale.
Tukey’s post hoc comparisons.
a AD versus a-MCI, p-value <0.05.
b aMCI versus HS, p-value <0.05.
c AD versus HS, p-value <0.05.
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cognitive efﬁciency: Mini-Mental State Examination (Folstein et al.,
1975; Measso et al., 1993). For the purposes of the present study,
neuropsychological scores were adjusted for age and education, as
reported in the corresponding references. Nineteen one-way
ANOVAs were used to assess between-group differences in neuro-
psychological performances. To avoid the type-I error Bonferroni
correction was applied (p value threshold a ¼ 0.05/19 ¼ 0.003).
For the neuropsychiatric assessment, AD and a-MCI patients’
caregivers were required to complete the Neuropsychiatric In-
ventory (NPI-12) (Cummings, 1997). This scale assesses the pres-
ence and severity of delusions, hallucinations, agitation/aggression,
dysphoria/depression, anxiety, euphoria/elation, apathy, disinhibi-
tion, irritability/lability, aberrant motor behavior, sleep, and eating
disturbances. Each item’s score ranges from 0 to 12 and reﬂects
both ratings of severity and frequency of each behavioral symptom,
with 0 corresponding to the absence of behavioral symptom and 12
corresponding to its maximum frequency and severity.
A factor analysis was used to extract in AD and a-MCI patients
main factors from NPI-12. Factor analysis describes variability
among observed correlated variables in terms of a potentially lower
number of unobserved variables called factors. In the present case,
we hypothesized that the factors represented the common variance
in the 12 subscales of NPI-12. Each NPI-12’s score (frequency by
severity) was entered as variables of interest in factor analyses.
Factor analyses were performed using the Maximum Likelihood
estimation method (with eigenvalues >1 for the factors’ extraction
and VARIMAX method for factors’ rotation). Factors extracted from
NPI-12 were then used in the MRI data analyses.
A trained psychologist screened HS to exclude any psycho-
pathological symptom on the basis of dedicated clinical interviews.
Statistics to assess differences in symptoms’ occurrence across
patients’ subgroups was performed using a series of c2 tests.
2.3. MRI acquisition
All imaging was obtained, in a single session, using a head only
3.0 T MRI scanner (Siemens Magnetom Allegra, Siemens Medical
Solutions, Erlangen, Germany). The MRI acquisition protocol
included (1) a dual-echo turbo spin echo (repetition time
[TR]¼ 6190 ms, echo times [TE]¼ 12/109ms, echo train length¼ 5;
matrix¼ 256 192; ﬁeld of view¼ 230172.5 mm2; 48 contiguous
3 mm thick slices); (2) a fast ﬂuid attenuated inversion recovery
(TR ¼ 8170 ms, TE ¼ 96 ms, inversion time ¼ 2100 ms; echo train
length¼ 13; with same ﬁeld of view,matrix, and number of slices asturbo spin echo), (3) 3D Modiﬁed Driven Equilibrium Fourier
Transform (MDEFT) scan (TR ¼ 1338 ms, TE ¼ 2.4 ms, matrix ¼
256  224, n slices ¼ 176, thickness ¼ 1 mm), (4) a T2*-weighted
echo-planar imaging sensitized to blood oxygenation level depen-
dent contrast (TR ¼ 2080 ms, TE ¼ 30 ms, 32 axial slices parallel to
anterior commissure-posterior commissure line, matrix ¼ 64  64,
pixel size ¼ 3  3 mm2, slice thickness ¼ 2.5 mm, ﬂip angle ¼ 70)
for resting-state fMRI (total number of volumes ¼ 220). During this
acquisition, subjects were instructed to keep their eyes closed, not
to think of anything in particular, and not to fall asleep.
2.3.1. Medial temporal lobe atrophy
The medial temporal lobe atrophy scale (MTA) (Scheltens et al.,
1995) was used to assess on volumetric images (MDEFT), the
presence and severity of atrophy in each subject. This scale provides
a rating score from 0 to 4, with scores 1.5 (Pereira et al., 2004)
indicating signiﬁcant atrophy. For each subject, we averaged the
scores obtained in the right and left hemispheres to obtain a single
measure of medial temporal lobe atrophy. One-way ANOVA was
used to control for between-group differences.
2.3.2. Image analysis of resting-state fMRI data
Images were preprocessed for resting-state fMRI using Statisti-
cal Parametric Mapping version 8 (SPM8, http://www.ﬁl.ion.ucl.ac.
uk/spm/), and in-house MATLAB scripts as previously described
(Bozzali et al., 2015). First, every participant’s MDEFT was
segmented in SPM8 to obtain participant-speciﬁc white matter and
cerebrospinal ﬂuid (CSF) masks, as well as to estimate the total grey
matter volume.
As both VTA and LC are very small, we followed a pipeline similar
to that described by Bär et al. (Bär et al., 2016). For each participant,
the ﬁrst 4 volumes of the fMRI series were discarded to allow for T1
equilibration effects. The preprocessing steps included correction
for head motion, compensation for slice-dependent time shifts, and
normalization to the echo-planar imaging template in Montreal
Neurological Insititute (MNI) coordinates provided with SPM8. For
each data set, motion correction was checked to ensure that the
maximum absolute shift did not exceed 1.5 mm and the maximum
absolute rotation did not exceed 1. Data sets not fulﬁlling these
criteria were removed. In addition, to minimize the risk that our
results were affected by differing degree of motion for the 3 par-
ticipants’ groups, we computed the global correlation (GCORR, Saad
et al., 2013), the average mean displacement (root mean square
[RMS] of the 6 realignment parameters), and the average framewise
displacement (FD, Power et al., 2012) and compared them between
L. Serra et al. / Neurobiology of Aging 72 (2018) 72e82 75AD and HS, and between MCI and HS, respectively, using indepen-
dent sample T-tests. The signal in every voxel was regressed against
the average white matter and CSF signals, as well as against the 6
realignment parameters. Then, all images were ﬁltered by a phase-
insensitive band-pass ﬁlter (pass band 0.01e0.08 Hz) to reduce the
effect of low-frequency drift and high-frequency physiological
noise. We refer to these data sets as unsmoothed corrected data.
These data were then smoothed via ﬁltering with a 3D Gaussian
kernel with 10 mm3 full width at half maximum.
2.3.3. Seed-based analyses
Standard space seed masks of the left and right VTA and LC were
produced using the Harvard Ascending Arousal Network Atlas in
MGH152_1 mm Space (https://www.martinos.org/) (Edlow et al.,
2012) (Fig. 1).
The mean time course within each seed region was extracted
(from the unsmoothed corrected data) for every participant (aver-
aged for left and right sides). This was done to minimize the partial
volume contamination from neighboring nuclei. The smoothed
data were then regressed voxelwise against these time courses in a
ﬁrst-level SPM8 analysis (Olivito et al., 2017). The resulting beta
images were taken to the second level for a random-effect group
analysis. At second level, 2 full factorial models (with a 3-level
factor modeling the group) were used to assess between-group
differences in VTA and LC FC, separately.
Next, we assessed the potential associations between the NPI-
12’s factors and FC changes in a-MCI and AD patients using multiple
regression models. To do that, we selected some a priori spherical
(radius ¼ 6 mm) regions of interest (ROIs), centered in the peak
coordinates of the clusters that showed differences in connectivity
between patients and controls. The mean connectivity in these
areas was extracted and correlated with the 5 factors using Pear-
son’s correlation coefﬁcient. In addition, we performed a more
exploratory analysis, looking at the whole brain is SPM. FiveFig. 1. Seed areas used to assess connectivity in VTA and LC. The ﬁgure illustrates the anato
blue). For the anatomical deﬁnition of VTA and LC, the Harvard AAN Atlas has been used (http
and LC are overlaid onto the Ch2bet template using mricron (http://people.cas.sc.edu/rorden
ventral tegmental area. (For interpretation of the references to color in this ﬁgure legend, tseparatewhole-brain analyses were performed for each factor. In all
analyses, whole-brain GM volumes and years of formal education
were entered as covariates of no interest. Statistical signiﬁcancewas
always set at p < 0.05 familywise error corrected at cluster level.
3. Results
3.1. Demographic and clinical characteristics
Therewere no signiﬁcant differences between groups in age and
gender distribution (Table 1). There were signiﬁcant differences
across groups in years of formal education.
3.2. Neuropsychological assessment
As expected, AD patients showed signiﬁcantly worse perfor-
mances than a-MCI patients and HS in each administered test. a-
MCI patients showed worse performances than HS in tests assess-
ing episodic memory and executive functions. Details of the neu-
ropsychological assessment are summarized in Table 2.
3.3. Neuropsychiatric assessment
Fig. 2 shows, for the NPI-12 subscale, the percentage of patients
who reported a score higher than 0.
As expected, patients with AD showed a signiﬁcantly higher
occurrence than patients with a-MCI in the following NPI-12 sub-
scales: delusions (15 of 84 AD patients [17.8%], vs. 1 of 48 a-MCI
patients [2.1%], c2 ¼ 7.13, df ¼ 1, p ¼ 0.007); agitation (34 of 84 AD
patients [40.5%], vs.11 of 48 a-MCI patients [22.9%], c2¼ 4.19, df¼ 1,
p ¼ 0.04); euphoria (10 of 84 AD patients [11.9%], vs. 1 of 48 a-MCI
patients [2.1%], c2 ¼ 3.86, df ¼ 1, p ¼ 0.04); disinhibition (19 of 84
AD patients [21.4%], vs. 4 of 48 a-MCI patients [4.8%], c2¼ 4.33, df¼
1, p ¼ 0.03); motor aberrant behavior (19 of 84 AD patients [21.4%],mical points used as seed to assess connectivity starting from VTA (in red) and LC (in
s://www.martinos.org/) (Edlow et al., 2012). For the purpose of the illustration, the VTA
/mricron/). Abbreviations: AAN, Ascending Arousal Network; LC, locus coeruleus; VTA,
he reader is referred to the Web version of this article.)
Table 2
Performance obtained by participants on neuropsychological testing
Neuropsychological test AD a-MCI HS F p-value
Verbal episodic memory
15-Word List:
Immediate recall (cutoff  28.5) 24.8 (8.8)a,b 30.9 (5.6)c 44.6 (8.8) F2.166 ¼ 77.15 0.000
Delayed recall (cutoff  4.6) 2.8 (2.4)a,b 4.4 (2.4)c 9.4 (2.3) F2.166 ¼ 94.78 0.000
Recognition hit rates 8.4 (3.9)a,b 10.7 (2.9)c 13.3 (1.6) F2.166 ¼ 25.05 0.000
Recognition false 6.3 (6.7)a,b 5.8 (5.2)c 1.7 (1.7) F2.166 ¼ 7.54 0.001
Short Story
Immediate recall (cutoff  3.1) 1.0 (1.7)a,b 3.3 (2.4)c 5.3 (1.5) F2.166 ¼ 55.70 0.000
Immediate recall (cutoff  2.8) 1.1 (1.9)a,b 3.7 (2.4)c 5.5 (1.5) F2.166 ¼ 50.41 0.000
Visuospatial episodic memory
Rey’s Complex Figure
Immediate recall (cutoff  6.4) 7.2 (5.2)a,b 10.9 (6.1)c 16.1 (6.6) F2.166 ¼ 24.66 0.000
Delayed recall (cutoff  6.3) 6.0 (5.3)a,b 9.9 (6.8)c 16.1 (5.6) F2.166 ¼ 31.41 0.000
Verbal short-term memory
Digit Span forward (cutoff  3.7) 4.8 (1.1)a 5.2 (0.9) 5.7 (1.1) F2.166 ¼ 10.19 0.001
Digit Span backward 2.8 (1.6)a,b 3.6 (1.3) 4.3 (0.7) F2.166 ¼ 15.53 0.000
Visuospatial short-term memory
Corsi Span forward (cutoff  3.5) 3.8 (1.5)a,b 4.5 (0.6) 5.1 (0.8) F2.166 ¼ 16.03 0.000
Corsi Span backward 2.8 (1.9)a,b 3.7 (1.2) 4.6 (0.9) F2.166 ¼ 13.61 0.000
Executive functions
Phonological verbal ﬂuency (cutoff  17.3) 23.0 (10.5)a,b 29.6 (6.7)c 36.3 (10.2) F2.166 ¼ 25.56 0.000
Modiﬁed Card Sorting Test Criteria achieved (cutoff  17.3) 2.3 (1.7)a,b 3.8 (2.0)c 5.7 (0.6) F2.166 ¼ 43.22 0.000
Reasoning
Raven’s Progressive Matrices (cutoff  18.9) 22.6 (8.0)a,b 27.0 (4.8)c 31.6 (3.7) F2.166 ¼ 25.26 0.000
Language
Naming of objects (cutoff  22) 24.4 (7.9)a,b 28.2 (1.9) 28.5 (2.1) F2.166 ¼ 8.94 0.001
Constructional praxis
Copy of drawings (cutoff  7.1) 7.6 (3.5)a,b 9.5 (1.8) 10.8 (1.1) F2.166 ¼ 18.15 0.000
Copy of drawings with landmarks (cutoff  61.8) 56.8 (19.1)a,b 66.5 (3.8) 69.3 (0.8) F2.166 ¼ 11.55 0.000
Rey’s Complex Figure Copy (cutoff 23.7) 22.9 (11.2)a,b 29.4 (7.1) 32.3 (3.6) F2.166 ¼ 14.22 0.000
Key: a-MCI, amnestic mild cognitive impairment; AD, Alzheimer’s disease; HS, healthy subjects.
Tukey’s post hoc comparisons.
a AD versus HS p-value <0.05.
b AD versus a-MCI p-value <0.05.
c a-MCI versus HS p-value <0.05.
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adjusting for multiple comparisons using Bonferroni correction
(threshold for signiﬁcance p ¼ 0.05/12 ¼ 0.004), only motor aber-
rant behavior remains signiﬁcantly different. Interestingly, the 2
groups of patients showed no statistical differences in the highFig. 2. Neuropsychiatric symptoms in patients with a-MCI and AD. The ﬁgure shows
the prevalence of behavioral symptoms in a-MCI (in blue) and AD (in red) patients, as
assessed by NPI-12. *AD versus a-MCI p < 0.05. Abbreviations: a-MCI, amnestic mild
cognitive impairment; AD, Alzheimer’s disease; NPI-12, Neuropsychiatric inventory-
12; A. Motor Behv, aberrant motor behavior. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the Web version of this article.)occurrence of the following NPI-12 subscales: depression (43 of 84
AD patients [51.1%], vs. 21 of 48 a-MCI patients [43.7%], c2 ¼ 0.68,
df¼ 1, p¼ 0.41); apathy (49 of 84 AD patients [58.3%], vs. 21 of 48 a-
MCI patients [43.7%], c2 ¼ 2.61, df ¼ 1, p ¼ 0.11); anxiety (39 of 84
AD patients [46.4%], vs. 21 of 48 a-MCI patients [43.7%], c2 ¼ 0.09,
df ¼ 1, p ¼ 0.77); irritability (37 of 84 AD patients [44.0%], vs. 18 of
48 a-MCI patients [37.5%], c2 ¼ 0.54, df ¼ 1, p ¼ 0.46); sleep dis-
orders (23 of 84 AD patients [27.3%], vs. 12 of 48 a-MCI patients
[25.0%], c2 ¼ 0.09, df ¼ 1, p ¼ 0.76); and eating disorders: (23 of 84
AD patients [27.3%], vs. 8 of 48 a-MCI patients [16.7%], c2 ¼ 1.95,
df ¼ 1, p ¼ 0.16). Finally, both patient groups showed low occur-
rence in hallucinations (4 of 84 AD patients [4.8%], vs.1 of 48 a-MCI
patients [2.1%], c2 ¼ 0.6, df ¼ 1, p ¼ 0.44).
Overall, apathy, depression, and anxiety were the most frequent
behavioral symptoms observed in our patient cohort, with no sig-
niﬁcant differences between AD and a-MCI.
From the initial 12 NPI subscales entered in the factor analysis
(see Table 3), 5 factors were extracted (54.9% of variance). The NPI-
12 subscales reporting a saturation threshold 0.35 (Overall and
Klett, 1972) were included in a factor as follows: agitation, irrita-
bility, and disinhibition in factor 1; hallucination and delusions in
factor 2; depression and apathy in factor 3; euphoria and aberrant
motor behavior in factor 4; eating and sleep disorders in factor 5.
Based on this classiﬁcation, 44 patients presented with the
symptoms grouped in factor 1 (31 AD and 13 a-MCI; c2 ¼ 1.33,
df ¼ 1, p ¼ 0.249), 22 patients with those in factor 2 (15 AD and 7 a-
MCI; c2 ¼ 0.24, df ¼ 1, p ¼ 0.627), 48 patients with those in factor 3
(31 AD and 17 a-MCI; c2 ¼ 0.03, df ¼ 1, p ¼ 0.864), 18 patients with
those in factor 4 (17 AD and 1 a-MCI; c2 ¼ 8.55, df ¼ 1, p ¼ 0.003),
and 34 patients with those in factor 5 (24 AD and 10 a-MCI;
c2 ¼ 0.96, df ¼ 1, p ¼ 0.328).
Table 3
Results of factor analysis in patients’ group
Total variance explained
Factor Initial eigenvalues Extraction sum of squares loadingsa Rotate extraction sum of squares loadingsb
Total % Of variance % Cumulative Total % Of variance % Cumulative Total % Of variance % Cumulative
1 3.36 28.02 28.02 2.22 18.48 18.48 1.67 13.91 13.91
2 1.60 13.27 41.30 0.80 6.70 25.17 1.43 11.95 25.85
3 1.24 10.30 51.59 1.73 14.42 39.60 1.35 11.27 36.13
4 1.19 9.89 61.48 1.18 9.84 49.43 1.19 9.96 47.09
5 1.02 8.50 69.98 0.67 5.56 54.99 0.95 7.90 54.99
6 0.88 7.36 77.34
7 0.69 5.78 83.12
8 0.55 4.63 87.74
9 0.49 4.10 91.84
10 0.38 3.13 94.97
11 0.37 3.07 98.04
12 0.23 1.95 100
Communalities and rotated factor matrix
Communalitiesa Rotated Factor Matrixb
Initial Extraction Factor 1 Factor 2 Factor 3 Factor 4 Factor 5
Delusions 0.29 0.25 0.17 0.37 0.25 0.13 0.03
Hallucination 0.48 0.99 0.01 0.97 0.10 0.20 0.09
Agitation 0.43 0.51 0.67 0.02 0.19 0.16 0.03
Depression 0.35 0.84 0.03 0.07 0.91 0.04 0.04
Anxiety 0.17 0.10 0.13 0.06 0.24 0.04 0.14
Euphoria 0.25 0.18 0.03 0.18 0.01 0.35 0.14
Apathy 0.36 0.39 0.27 0.09 0.52 0.05 0.17
Disinhibition 0.56 0.60 0.54 0.47 0.05 0.19 0.24
Irritability 0.53 0.72 0.80 0.05 0.23 0.05 0.14
Ab. Mot Beh. 0.34 0.99 0.23 0.12 0.05 0.96 0.07
Sleep 0.21 0.39 0.03 0.01 0.11 0.13 0.60
Eating disorder 0.41 0.62 0.32 0.26 0.07 0.09 0.65
Key: Ab. Mot Beh., aberrant motor behavior.
a Extraction method: Maximum likelihood.
b Rotation method: Varimax with Kaiser Normalization; the variables in bold included in each factor according to the saturation threshold  0.35 (Overall and Klett, 1972).
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None of the HS showed evidence of clinically relevant hippo-
campal atrophy (MTA 1). All patients (a-MCI and AD) reported
MTA scores signiﬁcantly higher than those reported HS (Table 1).3.5. Functional brain connectivity
3.5.1. Changes in FC within the brainstem monoaminergic nuclei
across AD stages
Four participants with AD,1 with a-MCI, and 1 HSwere removed
from the analysis because of excessive movement. After removing
them, there were no signiﬁcant differences between groups in any
of the following: GCORR (AD vs. HS, p ¼ 0.75; MCI vs. HS, p ¼ 0.17);
mean motion parameters RMS (AD vs. HS, p ¼ 0.24; MCI vs. HS, p ¼
0.47); mean FD (AD vs. HS, p ¼ 0.51; MCI vs. HS, p ¼ 0.47, and 0.51).
In HS, the VTA was functionally connected to the main nodes of
the DMN (see Fig. 3A), while LC was connected to some of the nodes
of the salience network (the insular cortices and with basal ganglia)
as well as with the orbitofrontal and the parahippocampal cortices
(Fig. 3B). Similar patterns were observed also in a-MCI and AD,
although qualitatively the connectivity appears reduced.
Quantitatively, compared to HS, patients with a-MCI showed
lower FC in VTA and in the right parietal lobule (BA7). AD patients
showed lower FC than HS between VTA and the posterior cingulate
cortex (PCC), precuneus, and parietal lobule bilaterally (BA7). No
changes were found in the opposite direction. These results are
summarized in Fig. 4. Conversely, when looking at LC connectivity,
there were no between-group changes that reached statistical sig-
niﬁcance. As discussed below (page 9), this is likely due to the low
resolution power of ourMRI data to LCwhose size is relatively small.3.5.2. Associations between monoaminergic brainstem nuclei
connectivity and prevalence of behavioral symptoms
Based on the results of the group comparison, ROI-based asso-
ciations were investigated in 3 ROIs: the PCC (MNI coordinates
[0 32 34]), the right angular gyrus (MNI coordinates [38 68 48]),
and the left angular gyrus (MNI coordinates [36 74 44]). No
signiﬁcant association was found.
For thewhole-brain analysis, signiﬁcant associations were found
between VTA connectivity and behavioral symptoms expressed by
factor 1 (i.e., agitation, irritability, and disinhibition) and factor 5
(i.e., sleep and eating disorders). Factor 1 was positively correlated
with connectivity between VTA and the right hippocampus, and the
cerebellum bilaterally. Factor 5 showed a positive correlation with
connectivity between VTA and the left putamen and inferior frontal
gyrus (see Fig. 5, green). The same factor was also negatively
correlated with FC between VTA and the left caudate (see Fig. 5,
magenta).4. Discussion
Over the last 10 years, it has become increasingly clear that
speciﬁc brainstem regions play a modulatory role in various
cognitive and behavioral aspects that accompany aging (Bartus
et al., 1982). Among them, VTA and LC are of particular interest,
as they are believed to cooperate in a number of physiological
functions from cognition to social behavior (Park et al., 2012). The
main goal of this study was to assess whether changes in VTA and
LC connectivitydused as a proxy of neuronal lossdare present in
AD and may account for higher level dysfunctions, as strongly
suggested by animal model evidence (Nobili et al., 2017). VTA
degeneration was indeed suggested to precede amyloid plaque
Fig. 3. Patterns of functional connectivity between VTA and LC and the rest of the brain across groups. (A) VTA connectivity. VTA was connected mainly with the nodes of default
mode network, with the mediotemporal regions and with basal ganglia (in panel A). This patternwas progressively less signiﬁcant moving from HS to AD. (B) LC connectivity. LC was
connected mainly with the orbito-frontal, the parahippocampal, the insular cortices, and with basal ganglia. The results are overlaid onto the Ch2bet template using mricron (http://
people.cas.sc.edu/rorden/mricron/). Abbreviations: a-MCI, amnestic mild cognitive impairment; AD, Alzheimer’s disease; FC, functional connectivity; HS, healthy subjects; L, left.
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Tredici, 2011a; Braak and Del Tredici, 2011b; Theoﬁlas et al., 2017)
was demonstrated in AD brains as associated to accumulation of
NFT (Andrés-Benito et al., 2017). For this reason, we included in our
study patients at early (a-MCI) and intermediate stages of AD. Theclinical, radiological (MTA) and neuropsychological characteristics
of our sample suggest a diagnosis of Alzheimer’s clinical syndrome
(Albert et al., 2011; Jack et al., 2018; McKhann et al., 2011). In line
with our hypothesis and with previous animal work (Nobili et al.,
2017), we found evidence of VTA disconnection with the right
Fig. 4. Reductions in VTA connectivity between patients and healthy controls. Patients with a-MCI compared to HS (in blue) showed reduced FC and the right parietal lobule. AD
patients compared to HS (in red) showed lower functional connectivity and PCC, and precuneus and parietal lobules bilaterally. The overlapping areas are shown in purple. The
results are FWE-corrected at cluster level (p < 0.05) and overlaid onto the Ch2bet template using mricron (http://people.cas.sc.edu/rorden/mricron/). Abbreviations: a-MCI, amnestic
mild cognitive impairment; AD, Alzheimer’s disease; FC, functional connectivity; FWE, familywise error; HS, healthy subjects; PCC, posterior cingulate cortex; L, left. (For inter-
pretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
Fig. 5. Correlations between neuropsychiatric factors and VTA connectivity. Of the 5 factors explaining most of the variance in NPI-12 (see text), we found signiﬁcant associations of
VTA connectivity with factor 1 (agitation, irritability, and disinhibition) and with factor 5 (eating and sleep disorders). Direct associations with factor 1 were found in the right
hippocampus and the cerebellum bilaterally (top left, in cyan). Both positive (in green) and negative (in magenta) associations were found with factor 5 (bottom), in left putamen/
inferior frontal gyrus and the left caudate, respectively. The results are FWE-corrected at cluster level (p < 0.05) and overlaid onto the Ch2bet template using mricron (http://people.
cas.sc.edu/rorden/mricron/). Abbreviations: FWE, familywise error; L, left. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version
of this article.)
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previous observations that degeneration of dopaminergic neurons
in VTA is already present in the preplaque mouse model of AD stage
(Nobili et al., 2017). In the animal model, VTA degeneration was
found to contribute to the memory deﬁcits and dysfunction of
reward processing (Nobili et al., 2017), which are regarded as
motivated behaviors. In AD, the pattern of VTA disconnection
extended to additional parietal areas, with a substantial involve-
ment of the cingulate cortex and precuneus. These ﬁndings support
the hypothesis of a progressive degeneration on VTA neurons with
AD progression. Interestingly, this pattern largely overlaps with the
major nodes of the so-called DMN (Gili et al., 2011), including the
PCC and precuneus, and the right parietal node. AD patients were
characterized by amore extensive disconnection in these areas than
patients with a-MCI. It was previously argued that disconnection in
the PCC is a critical transitional step for the conversion from a-MCI
to AD (Bozzali et al., 2012; Gili et al., 2011). In addition, VTA and the
substantia nigra pars compacta were demonstrated being func-
tionally connected to regions of the DMN in healthy controls (Bär
et al., 2016). Our current ﬁndings suggest that the often reported
disconnection within the DMN (Seeley et al., 2009) might not be
caused only by loss of neurons from the medial temporal lobes, but
also associated with VTA dysfunction. In contrast to our working
hypothesis and previous literature (Braak and Del Tredici, 2011a;
Braak and Del Tredici, 2011b; Theoﬁlas et al., 2017; Andrés-Benito
et al., 2017; Jacobs et al., 2015), we were unable to identify any
signiﬁcant changes in FC between LC and the rest of the brain in
both patient groups (at the statistical thresholds chosen for this
study). Considering the small size of LC, we argue that this nucleus
is below the resolution power of ourMRI data, and therefore, we are
unable to draw conclusions about LC connectivity in our patient
cohort. Admittedly, Jacobs et al. (2015), using resting-state fMRI,
have previously reported reduced LC connectivity with the para-
hippocampal gyrus in patients with a-MCI that correlated with
memory performance (Jacobs et al., 2015). There are some technical
differences that might at least partially account for the inconsis-
tency of our current results. First, Jacobs and coauthors warped the
seed masks into each participant’s native space, while we extracted
the time series from warped data and then used smoothed data
(4 mm full width at half maximum). Second, they used a different
method to correct for multiple comparisons. We also observed
some connectivity changes in the LC of AD patients when using less
stringent statistical thresholds (data not shown).
From a clinical point of view, VTA degeneration has been
recently associated to memory dysfunction in AD and a-MCI pa-
tients (De Marco & Venneri, 2018). The dopaminergic system is
known to be remarkably implicated in behavioral and psychological
aspects; thus, the loss of dopaminergic neurons could be particu-
larly relevant for the manifestation of psychiatric symptoms in AD.
These symptoms are frequently observed in AD and are known to
become increasingly worse along with disease progression (Alves
et al., 2017; Masters et al., 2015). Behavioral symptoms have been
previously reported also in a-MCI patients, although they have not
been univocally associated with neurodegeneration (Gonsalvez
et al., 2017; Makovac et al., 2016; Serra et al., 2010). To establish
whether VTA degeneration and disconnection could account for
behavioral symptoms, we investigated the association between VTA
FC and NPI-12 factors.We could not ﬁnd clear evidence that the loss
of connectivity between VTA and the nodes of the DMN impacts on
behavioral symptoms. However, in amore exploratory, whole-brain
analysis, we found signiﬁcant associations with factor 5 (including
sleep and eating disorders) and with factor 1 (including agitation,
irritability and disinhibition). Interestingly, factor 5 showed both
increased VTA connectivity mainly in the putamen and reduced
connectivity in the caudate. The basal ganglia play a well-knownrole in regulating sleep and wakefulness (Rolinski et al., 2016),
and sleeping disorders are frequently associated with other
neurological diseases, such as Parkinson’s disease, that affect the
basal ganglia. Moreover, reduced activity in the caudate has been
found also in the subject suffering from insomnia (Stoffers et al.,
2014). In addition, we found also increased connectivity related to
factor 1 in the hippocampus and in the cerebellum, 2 brain areas
innervated by VTA dopaminergic neurons (Ikai et al., 1992).
The association with the cerebellum is particularly intriguing
considered its contribution to the cognitive and neuropsychiatric
deﬁcits in AD (Jacobs et al., 2018; Vermeiren et al., 2014) and the
role of dopamine in the cerebellum functions beyond the coordi-
nation of voluntary motor activity and motor learning. We previ-
ously found an association between hippocampal atrophy and
positive behavioral symptoms in patients with AD (Serra et al.,
2010). Unexpectedly, the direction of this correlation suggests
that increased connectivity between these areas and VTA are
associated with worsening in behavioral symptoms. As we did not
ﬁnd any evidence of increased connectivity between the areas of
the DMN and VTA, an intriguing interpretation (although very
speculative at this stage) is that disengagement of the VTA from the
DMN might lead to an increased connectivity between the same
area and the salience network.
This study also suffers from some limitations. First of all, VTA
and LC are very small nuclei, and they are difﬁcult to identify on
MRI. It is therefore possible that some of our results are affected by
partial volume with neighboring structures of the brainstem.
Nevertheless, we have tried to minimize these effects by extracting
the time series from unsmoothed data. Another potential confound
comes from respiration and pulsatility artifacts, to which these
areas are particularly susceptible. Ideally, these can be accounted
for when acquiring respiration data concomitant with fMRI. Un-
fortunately, we did not have these data.We could have also adopted
more sophisticated postprocessing approaches, such as regressing
out GCORR (Saad et al., 2013) or complementing whole-brain cor-
egistration with a further, brainstem-weighted registration
(Napadow et al., 2006). Nevertheless, the comparisons we
computed for 3 parameters reﬂecting global motion (GCORR, RMS,
and FD) suggest that it was comparable among groups. Third, we
deﬁned the nuclei using an atlas in standard space (due to the
aforementioned difﬁculties in identifying each nucleus on subject-
speciﬁcMRI). Amore accurate location could have been achieved by
registering the standard ROI to each participant’s scan (Jacobs et al.,
2015). In addition, if the nuclei under observation are characterized
by macroscopic atrophy, it is possible that this might inﬂuence the
results of our connectivity analysis. However, for the motivations
explained previously, it is not possible to measure the volume of
each nucleus independently, and thus adjust for this potential
confound. Finally, we did not have access to information of amyloid
in our cohort, either from CSF analysis or photon emission tomog-
raphy imaging. This information would increase the diagnostic
conﬁdence, particularly in view of the most recent criteria, which
require amyloid and tau biomarkers for the diagnosis of AD (Jack
et al., 2018). Unfortunately, these biomarkers were not available
in our cohort of patients and this is a limitation of the study. It is
therefore possible that some of the participants might have other
forms of dementia, such as fronto-temporal lobar degeneration.
Nevertheless, this is highly unlikely because the whole cohort
showed clinical (episodic memory disorder at onset), radiological
(hippocampal atrophy) and neuropsychological (memory disorders
conﬁrmed by formal tests) features suggesting the presence of an
Alzheimer’s clinical syndrome at different clinical stages (Albert
et al., 2011; Jack et al., 2018; McKhann et al., 2011).
In addition, despite the performance of patients with AD at
language tests (naming of objects) being signiﬁcantly worse than
L. Serra et al. / Neurobiology of Aging 72 (2018) 72e82 81that of controls and a-MCI participants, on average, it was still
within the range of normality (mean ¼ 24, cutoff ¼ 22), thus
minimizing the likelihood that they had frontotemporal degener-
ation. Because of the speciﬁc focus of this study, it would have been
useful also tomeasure dopamine levels to support theMRI ﬁndings.
In summary, the present study has identiﬁed a progressive
functional disconnection between VTA and several brain regions,
measurable since the a-MCI stage. These FC changes are likely to
reﬂect a progressive dopaminergic dysregulation, and it might ac-
count for several behavioral symptoms, including circadian disor-
ders and agitation, irritability, and disinhibition observed in both a-
MCI and AD patients. Although the role of dopaminergic system in
early AD patients is not fully explored, this clinical investigation
providing compelling evidence of altered connectivity between
VTA and some key brain regions involved in AD pathology.Disclosure statement
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